Industry Insights
-
"How I Feel" – The Critical Role Of The Patient Perspective And How To Collect It
9/28/2026
Not sure how to capture what patients really experience? Explore five research methods, their strengths and limitations, and how early patient insight can sharpen trial design and development decisions.
-
How Digital Twins Are Reshaping Clinical R&D
9/28/2026
Discover how digital twins are helping predict outcomes, streamline recruitment, reduce patient burden, and accelerate clinical development.
- Why Are We Still Talking About Compensating Research Participants? 9/28/2026
-
Examining The Potential Of P-tau217 To Provide Earlier Diagnosis Of Alzheimer's
9/25/2026
P-tau217 blood tests could accelerate Alzheimer’s diagnosis. Lilly’s Nino Sireci, MD, MSc, explains the research, evidence thus far, potential clinical use, and next steps.
-
Early‑Phase Autoimmune Drug Development
9/24/2026
Adaptive designs and biomarker tracking help early autoimmune trials find true signals despite complex, variable disease patterns.
-
NIH To Extend Plain Language Results Requirement To Funded Studies
9/24/2026
New draft policy may require plain-language result summaries for clinical research participants. See what's in scope and how to prepare.
-
The 50-Page Monitoring Report And The Illusion Of Control
9/24/2026
A massive decentralized trial showed why more monitoring doesn’t always mean more control — and how risk-based oversight can reveal what truly matters.
-
Autoimmune Drugs For Women: What To Bring To The Clinic
9/24/2026
Autoimmune disease is one of the most sex-skewed categories in medicine. Sex, reproductive status, and hormonal state should not be treated as background noise.
-
The Real Cost Of Sites Working Without An Enforceable Agreement: Why Your Site's Quality Of Earnings Is Suspect
9/23/2026
Starting site work before an enforceable agreement may look like flexibility, but it can drain leverage, create unrecoverable costs, and raise financial reporting and GCP concerns.
-
Defining Meaningful Anti-Inflammatory Response: What Early Human Data Tells Us
9/22/2026
Controlled immune challenges link drug exposure to biological effects, helping refine dose selection, test mechanisms and support better decisions before patient trials.